Last updated date
ABOUT THIS STUDY
The German Spondyloarthritis Inception cohort (GESPIC) was started 2000 as a prospective,
longitudinal, multicentre, nationwide study in Germany on patients with early SpA including
ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and
non-radiographic axial SpA. The objectives of GESPIC are to learn about the course of SpA
during the very early stage of the disease, to appropriately assess the outcome including
radiographic progression of patients after several years of follow-up, to identify outcome
predictors, to assess quality of life, function, and costs (direct and indirect costs).
GESPIC has been recently expanded to recruit patients with other forms of SpA / conditions
associated with SpA: acute anterior uveitis, Crohn's disease as well as with psoriasis /
axial psoriatic arthritis.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
+4930450514582
Eligibility Criteria
condition
Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
Sex
Females and Males
Age
0 +
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Ankylosing Spondylitis, Non-radiographic Axial SpondyloarthritisGerman Spondyloarthritis Inception Cohort
NCT01277419
- Berlin,
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information